CRIS Current Research Information System

POLUZZI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.577
AS - Asia 13.427
EU - Europa 10.429
Continente sconosciuto - Info sul continente non disponibili 834
AF - Africa 821
SA - Sud America 772
OC - Oceania 46
Totale 40.906
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.273
SG - Singapore 3.574
CN - Cina 3.249
VN - Vietnam 3.167
IT - Italia 2.972
GB - Regno Unito 2.039
DE - Germania 1.545
HK - Hong Kong 1.207
SE - Svezia 847
IN - India 585
FR - Francia 574
BR - Brasile 565
RU - Federazione Russa 449
UA - Ucraina 376
NL - Olanda 360
KR - Corea 332
BD - Bangladesh 317
IE - Irlanda 314
JP - Giappone 284
CI - Costa d'Avorio 283
FI - Finlandia 217
TG - Togo 213
CA - Canada 176
ZA - Sudafrica 167
EE - Estonia 107
PH - Filippine 94
AT - Austria 90
ID - Indonesia 86
AR - Argentina 84
JO - Giordania 82
BE - Belgio 81
TH - Thailandia 73
PL - Polonia 69
TR - Turchia 69
ES - Italia 62
BG - Bulgaria 61
CH - Svizzera 58
MX - Messico 57
IQ - Iraq 45
TW - Taiwan 43
NG - Nigeria 37
AU - Australia 36
SC - Seychelles 36
PT - Portogallo 35
SA - Arabia Saudita 35
PK - Pakistan 33
HR - Croazia 29
UZ - Uzbekistan 28
GR - Grecia 27
CO - Colombia 26
EC - Ecuador 24
IR - Iran 20
LT - Lituania 20
CL - Cile 19
RO - Romania 19
MA - Marocco 18
VE - Venezuela 18
JM - Giamaica 16
CZ - Repubblica Ceca 15
IL - Israele 15
KE - Kenya 15
MY - Malesia 15
PE - Perù 14
PY - Paraguay 13
DK - Danimarca 11
EG - Egitto 11
LB - Libano 11
TN - Tunisia 11
AE - Emirati Arabi Uniti 10
NZ - Nuova Zelanda 10
GT - Guatemala 9
CR - Costa Rica 8
SK - Slovacchia (Repubblica Slovacca) 8
NI - Nicaragua 7
SY - Repubblica araba siriana 7
UY - Uruguay 7
HN - Honduras 6
KZ - Kazakistan 6
NP - Nepal 6
RS - Serbia 6
SI - Slovenia 6
TT - Trinidad e Tobago 6
DZ - Algeria 5
GH - Ghana 5
HU - Ungheria 5
SM - San Marino 5
AL - Albania 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
ET - Etiopia 4
MT - Malta 4
OM - Oman 4
XK - ???statistics.table.value.countryCode.XK??? 4
CY - Cipro 3
KH - Cambogia 3
LK - Sri Lanka 3
LY - Libia 3
MD - Moldavia 3
PA - Panama 3
PS - Palestinian Territory 3
Totale 40.024
Salva come PNG Salva come JPEG
Città #
Singapore 2.465
Southend 1.694
Ashburn 1.610
Hong Kong 1.114
Fairfield 914
Chandler 901
San Jose 878
Ho Chi Minh City 744
Hefei 728
Santa Clara 704
Dong Ket 595
Hanoi 554
Bologna 552
Wilmington 460
Frankfurt am Main 453
Princeton 417
Woodbridge 409
Council Bluffs 402
Houston 393
Beijing 392
Seattle 391
Ann Arbor 362
Boardman 334
Los Angeles 327
Seoul 306
Dublin 303
Cambridge 296
Abidjan 283
Dallas 260
Tokyo 221
Lauterbourg 218
Lomé 213
Jacksonville 209
Milan 209
New York 186
Rome 180
Helsinki 179
Westminster 146
Nanjing 143
Buffalo 127
Padova 127
Berlin 120
Redmond 114
São Paulo 100
Turin 91
Da Nang 86
Saint Petersburg 84
Shenyang 82
Amman 81
Redondo Beach 81
Haiphong 80
Bremen 79
Shanghai 79
Jinan 78
Medford 78
London 76
Florence 72
The Dalles 72
Bengaluru 69
Brussels 69
San Diego 67
Orem 66
Chicago 63
Munich 59
Mülheim 57
Toronto 57
Sofia 56
Guangzhou 55
Jakarta 54
Phoenix 51
Falkenstein 50
San Francisco 50
Vienna 50
Atlanta 49
Nanchang 48
Falls Church 47
Hebei 47
Nuremberg 44
Zhengzhou 42
Warsaw 41
Amsterdam 40
Changsha 40
Bern 39
Dearborn 39
Tianjin 38
Biên Hòa 37
Biella 36
Des Moines 36
Modena 35
Bangkok 34
Secaucus 34
Brooklyn 33
Jiaxing 33
Naples 33
Hangzhou 32
Istanbul 32
Redwood City 31
Abeokuta 30
Olalla 30
Palermo 30
Totale 24.735
Salva come PNG Salva come JPEG
Nome #
'Use of antipsychotics in children and adolescents: A picture from the ARITMO population-based European cohort study' 787
Leucoencefalopatia Multifocale Progressiva: complicanza dell'immunosoppressione o reazione avversa da farmaci? 623
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance 496
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. 493
Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. 420
ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance 384
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 349
Pro-arrhythmic potential of oral antihistamines (H1): Combining adverse event reports with drug utilization data across Europe 337
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals 327
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions 319
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage 315
Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) 310
Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project 308
Farmacoutilizzazione in ospedale: analisi delle variabilità in una realtà regionale 294
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 293
Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors 292
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems 282
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies 281
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System 276
Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy 263
Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study 253
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 247
Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. 245
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 241
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 239
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection 239
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 239
Pattern of drug use among preterm neonates: Results from an Italian neonatal intensive care unit 238
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 235
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database 235
A 3 year survey on the use of antibacterial agents in five Italian hospitals. 230
Emilia-Romagna Study on Pregnancy and Exposure to Antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health 229
Antibacterial macrolides: a drug class with a complex pharmacological profile 223
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database 223
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 220
Predictors of antipsychotic prescription in a Northern Italian District (Bologna) 220
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 219
Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy 217
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 217
Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement 216
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. 216
Antimicrobials and the Risk of Torsades de Pointes. The Contribution from Data Mining of the US FDA Adverse Event Reporting System 214
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System 211
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 209
Association between Paraesthesia and Local Anesthetics: Data Mining of the Public Version of the FDA Adverse Event Reporting System, 205
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis 205
Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study 205
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 205
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 203
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 202
Deprescribing as a strategy for improving safety of medicines in older people: Clinical and regulatory perspective 200
Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey 199
Social and clinical descriptors of antipsychotic prescription 197
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System 197
Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study 195
Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database 194
Drug-induced Kounis syndrome: A matter of pharmacovigilance 194
The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project 193
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 192
An approach to evaluate appropriateness in the antibacterial therapy in Italian hospitals. 191
Prescription patterns of antiepileptic drugs in young women: development of a tool to distinguish between epilepsy and psychiatric disorders 191
An update on the first decade of the European centralized procedure: how many innovative drugs? 190
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. 190
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting 189
The interface of depression and diabetes: treatment considerations 188
Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis 188
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study 187
Clinically important drug-drug interactions in poly-treated elderly outpatients: A campaign to improve appropriateness in general practice 187
Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region 187
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement 185
Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants 185
Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development 185
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping 185
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System 184
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 183
Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics 183
Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study 183
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction 180
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency 179
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 179
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 176
Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study 175
Changes in prevalence and pattern of drug use in a ten years period in Italy. 8th Congress of the European Association for Clinical Pharmacology and Therapeutics 175
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus 174
The hERG K+ channel: target and antitarget strategies in drug development. 172
Paraesthesia after Local Anaesthetics: An Analysis of Reports to the FDA Adverse Event Reporting System 172
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 172
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 171
Attitudes, barriers, and facilitators toward tools supporting appropriate prescribing among healthcare professionals: a cross-sectional study 171
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 168
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 167
Antimicrobial-induced torsades de pointes: towards risk stratification by data mining of the FDA Adverse Event Reporting System. 167
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration 166
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature 166
Predictors of non-adherence with oral bisphosphonates: an Italian retrospective cohort study on administrative databases 164
La condivisione dei trattamenti farmacologici in psichiatria e la percezione degli effetti avversi ai farmaci antipisicotici da medico, paziente e familiare 164
Farmaci lassativi e purganti 163
Excipients in medicinal products used in gastroenterology as a possible cause of side effects. 163
Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective 163
Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies 162
Totale 23.180
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.486
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 362
Totale 112.848
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.430 0 121 201 192 318 226 160 267 169 229 919 628
2022/20234.598 505 599 350 549 276 322 171 304 725 189 385 223
2023/20242.067 123 226 227 297 161 209 88 344 46 133 127 86
2024/20256.024 379 780 562 367 933 372 376 259 141 375 313 1.167
2025/202615.074 1.153 1.361 1.309 906 1.512 1.096 2.101 484 2.370 1.192 818 772
2026/20271.371 635 736 0 0 0 0 0 0 0 0 0 0
Totale 40.906